Drug intelligence / Profile preview

sorafenib + zoledronic acid

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy of sorafenib and zoledronic acid used for the treatment of hepatocellular carcinoma. Sorafenib is a multiple kinase inhibitor that inhibits the Raf/MEK/ERK signaling pathway to decrease tumor growth and angiogenesis, while zoledronic acid is a bisphosphonate that depletes macrophages. The combination has shown synergistic effects in inhibiting tumor progression, angiogenesis, and metastasis compared to sorafenib alone.

Targets

PDGFRB (Platelet-derived growth factor receptor beta)FDPS (Farnesyl pyrophosphate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)BRAF V600ERAF1 (c-Raf-1 (Y340D/Y341D))VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on sorafenib + zoledronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sorafenib + zoledronic acid.

Explore the full profile